By the Top Tier Newswire AI Desk · September 11, 2026 at 9:53 AM ET · reviewed against 3 wire stories
PHARVARIS N V (PHVS) is up +6.37% in the latest session. Our newswire has captured 3 stories on PHVS across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why PHVS stock is up today
Pharvaris N.V. stock rose 6.37% to $39.90 on Wednesday, driven by positive developments in its clinical trials and a series of analyst upgrades. The company released topline results from a Phase III study of deucrictibant for the prophylactic treatment of hereditary angioedema. This was followed by Guggenheim raising its price target for the stock to $44 from $40. The stock opened with a 2.6% gap up and traded in a volatile range before settling near the session high.
What Happened
Pharvaris N.V. published a slide deck outlining the topline results of its Chapter-3 Phase III study on deucrictibant, a drug candidate for the treatment of hereditary angioedema. This milestone in the clinical development of the drug was followed by an analyst action from Guggenheim, which raised its price target to $44. Additional external context came from other analysts, including Morgan Stanley, Leerink Partners, and RBC Capital, who also raised their price targets for the stock. These developments contributed to the stock’s strong performance on Wednesday.
What The Data Shows
The stock opened at $38.50, a 2.6% gap up from the prior close of $37.51. It reached a session high of $40.34 at 9:50 AM ET before retreating slightly. The stock closed at $39.90, with a volume of 0.1M shares, which is 0.2 times the 3-month daily average. Over the past 8 sessions, the stock has gained 9.5%, rising from $34.63 to $37.93. Additionally, the 52-week tape showed 10 fresh 52-week highs and one fresh 52-week low on the same day. Insider transactions in the last 90 days totaled $6.1M in sales, with no insider buying activity.
What To Watch
Pharvaris N.V. has no scheduled earnings date in the immediate future. Investors should monitor the breadth of analyst coverage and any further developments in the company’s clinical trials or regulatory process.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
PHVS · Sep 11 session (5-min) · +1.57% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 3 stories · 57/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
2d agoSeeking AlphaNEUTRAL 50General
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema - Slideshow
2026-09-10. The following slide deck was published by Pharvaris N.V.
3d agoInvesting.com Analyst RatingsBULLISH 61Analyst
Guggenheim raises Pharvaris stock price target on trial results
Guggenheim raises Pharvaris stock price target on trial results
3d agoThe FlyBULLISH 61Analyst
Pharvaris price target raised to $44 from $40 at Guggenheim
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →